Clinical trial readout dates for Kailera Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is May 2027.
| Phase 2 Ribupatide Obesity · NCT07458269 | May 2027 Ongoing |
| Phase 2 KAI-7535 Obesity; Overweight · NCT07497880 | July 2027 Ongoing |
| Phase 3 Ribupatide Obesity; Overweight · NCT07284875 | February 2028 Ongoing |
| Phase 3 Ribupatide Obesity · NCT07284979 | March 2028 Ongoing |
| Phase 3 Ribupatide Obesity With Diabetes; Overweight With Diabetes · NCT07284901 | March 2028 Ongoing |
Kailera Therapeutics Inc. reported $1.17B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). Its net loss for that quarter was $96M; at that rate the cash would last about 12 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-04 |